Accessibility Menu
Treace Medical Concepts logo

Treace Medical Concepts(NASDAQ) TMCI

Current Price$4.24
Market Cap$274.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-83%
5 Year-85%
1 Year-25%
1 Month+1%
Treace Medical Concepts last closing stock price
MetricPriceDate
Last closeUSD 4.232026-07-20
Treace Medical Concepts stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.64%USD 4.582026-07-13
1 month+0.95%USD 4.192026-06-18
3 month+131.15%USD 1.832026-04-21
Year to date+72.65%USD 2.452025-12-31
1 year-25.13%USD 5.652025-07-18
3 year-82.38%USD 24.012023-07-21
5 year-85.02%USD 28.242021-07-21
Since inception-83.43%USD 25.532021-04-23

Treace Medical Concepts Financials at a Glance

Market Cap

$274.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$207.32M

Net Income (TTM)

-$61.04M

EPS (TTM)

-$0.96

P/E Ratio

-4.42

Dividend

$0.00

Beta (Volatility)

1.29 (Average)

Price

$4.24

Volume

3,707

Open

$4.20

Previous Close

$4.23

Daily Range

$4.17 - $4.28

52-Week Range

$1.17 - $7.78

Estimated Earnings Date

Aug 6, 2026

TMCI News

Foolcom-Featured.png

Treace Medical (TMCI) Q2 Revenue Up 7%

Motley Fool Markets TeamAug 7, 2025
surgeon working in operating room

Why Treace Medical Concepts' Shares Rose Wednesday

James HalleyMar 8, 2023

TMCI: Motley Fool Moneyball Superscore

44

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Treace Medical Concepts

Treace Medical Concepts, Inc. focuses on advancing the surgical management of bunions and related midfoot deformities. It offers innovative solutions aimed at correcting bunion deformities through unique three-dimensional methodologies.

Products and Services

Lapiplasty® 3D Bunion Correction System: Corrects bunions in three dimensions, addressing their root causes.

Adductoplasty Midfoot Correction System: Provides surgical solutions for midfoot realignment and stability.

Hammertoe PEEK Fixation System: Treats hammertoe, claw toe, and mallet toe deformities.

SpeedPlate Rapid Compression Implants: Offers versatile titanium implants for various foot surgeries.

What Makes Treace Medical Concepts, Inc. Special

Treace Medical Concepts stands out due to its proprietary Lapiplasty® System, which corrects bunion deformities in all three dimensions, reducing recurrence rates compared to traditional procedures. This method not only improves surgical outcomes but also swiftly restores patients to weight-bearing activities.

Five Things You Need to Know

Treace's Lapiplasty® System is a pioneer in 3D bunion correction, offering a $2.3 billion market opportunity.

The company employs a direct-to-patient outreach program, enhancing both patient and physician education.

Its innovative procedures and products have led to progressive sales growth, with revenue reaching $187.1 million in 2023.

Surgeons are required to complete training before performing Lapiplasty procedures, ensuring consistent outcomes.

Patient studies demonstrate low rates of bunion recurrence and a quick return to daily activities.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

450

CEO

John T. Treace

Website

www.treace.com

Headquarters

Ponte Vedra, FL 32081, US

TMCI Financials

Key Financial Metrics (TTM)

Gross Margin

79.72%

Operating Margin

-26.89%

Net Income Margin

-29.44%

Return on Equity

-69.50%

Return on Capital

-53.45%

Return on Assets

-33.16%

Earnings Yield

-22.62%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$274.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.87M

Volume

3.71K

Avg. Volume

738.92K

Financials (TTM)

Gross Profit

$165.27M

Operating Income

-$55.74M

EBITDA

-$46.33M

Operating Cash Flow

-$12.93M

Capital Expenditure

-$13.04M

Free Cash Flow

-$25.97M

Cash & ST Invst.

$51.85M

Total Debt

$13.55M

Treace Medical Concepts Performance Analysis

Treace Medical Concepts annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 141,838,00050.2%
20232023-12-31USD 187,118,00031.9%
20242024-12-31USD 209,357,00011.9%
20252025-12-31USD 212,690,0001.6%
Treace Medical Concepts sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-9.9%
Q32025-09-306.0%
Q42025-12-3124.5%
Q12026-03-31-24.5%
Treace Medical Concepts annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.77102.3%
20232023-12-31USD -0.815.1%
20242024-12-31USD -0.9010.3%
20252025-12-31USD -0.933.9%
Treace Medical Concepts sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-12.0%
Q32025-09-307.1%
Q42025-12-3142.3%
Q12026-03-31-86.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$47.20M

-10.2%

Gross Profit

$37.41M

-10.7%

Gross Margin

79.26%

N/A

Market Cap

$274.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$609.81K

N/A

Employees

450

N/A

Net Income

-$17.96M

-12.8%

EBITDA

-$15.49M

-27.5%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$51.85M

-31.9%

Total Debt

$13.55M

-80.5%

Accounts Receivable

$30.36M

-2.4%

Inventory

$36.37M

-4.1%

Long Term Debt

$13.55M

-79.9%

Short Term Debt

$0.00

-100.0%

Return on Assets

-33.16%

N/A

Return on Invested Capital

-37.26%

N/A

Free Cash Flow

$4.17M

+536.9%

Operating Cash Flow

$7.23M

+72.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SMLRSemler Scientific, Inc.
$20.33-4.87%
RXSTRxSight, Inc.
$5.46-2.75%
LABStandard BioTools Inc.
$0.86+0.88%
EOLSEvolus, Inc.
$5.86+5.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$6.71+2.88%
NOKNokia
$10.71+0.06%
UTZUtz Brands
$14.11+0.89%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.41+0.06%

Questions About TMCI

What is the current price of Treace Medical Concepts?

Treace Medical Concepts is trading at $4.24 per share.

What is the 52-week range for Treace Medical Concepts?

Over the past 52 weeks, Treace Medical Concepts has traded between $1.17 and $7.78.

How much debt does Treace Medical Concepts have?

As of the most recent reporting period, Treace Medical Concepts reported total debt of $71.60M.

How much cash does Treace Medical Concepts have on hand?

Treace Medical Concepts reported $9.54M in cash and cash equivalents in its most recent financial results.

What is Treace Medical Concepts’s dividend yield?

Treace Medical Concepts does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services